Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
9.15
-0.13 (-1.40%)
At close: Jun 27, 2025, 4:00 PM
9.12
-0.03 (-0.33%)
After-hours: Jun 27, 2025, 7:56 PM EDT
Sage Therapeutics Revenue
Sage Therapeutics had revenue of $14.06M in the quarter ending March 31, 2025, with 77.97% growth. This brings the company's revenue in the last twelve months to $47.40M, down -47.94% year-over-year. In the year 2024, Sage Therapeutics had annual revenue of $41.24M, down -52.30%.
Revenue (ttm)
$47.40M
Revenue Growth
-47.94%
P/S Ratio
11.79
Revenue / Employee
$134,289
Employees
353
Market Cap
572.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.24M | -45.21M | -52.30% |
| Dec 31, 2023 | 86.46M | 78.77M | 1,024.84% |
| Dec 31, 2022 | 7.69M | 1.38M | 21.85% |
| Dec 31, 2021 | 6.31M | -1.11B | -99.43% |
| Dec 31, 2020 | 1.11B | 1.11B | 16,123.06% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SAGE News
- 5 days ago - Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 9 days ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire
- 10 days ago - These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
- 10 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - Accesswire
- 10 days ago - Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 11 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - PRNewsWire
- 12 days ago - Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know. - Barrons
- 12 days ago - Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - Reuters